Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.
- Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T.
- Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T.
About Abcuro
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.
For more information, visit us on LinkedIn and at abcuro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829770488/en/
Contacts
Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this article